Giovanni Capretti
Milan, Italy
Location status: Recruiting
Location contact
Alessandro Zerbi, Prof.
PRINCIPAL_INVESTIGATOR
Giovanni Capretti, Dr.
CONTACT
Giovanni Capretti, Dr.
SUB_INVESTIGATOR
NCT Number: NCT06381362
Assess the prevalence of minimally invasive pancreatic surgery in the country and its outcomes
Interested in participating?
Request Info18 year and older
All sexes
Observational
Milan, Italy
Location status: Recruiting
Alessandro Zerbi, Prof.
PRINCIPAL_INVESTIGATOR
Giovanni Capretti, Dr.
CONTACT
Giovanni Capretti, Dr.
SUB_INVESTIGATOR
Since 1994, when the first pancreatectomy surgeries, distal and proximal, conducted minimally invasively, were published, efforts have been made to understand the value of this approach in the context of a surgery as complex and burdened with specific complications as pancreatic surgery. The adoption of such an approach with regard to pancreatic surgery has been less rapid and parceled out than in other surgical fields and not supported by a large body of scientific publications. However, worldwide, referral centers for pancreatic surgery routinely use the minimally invasive approach in selected cases, and its diffusion has recently shown a marked increase. Even in Italy, a recent survey promoted by some of the major surgical societies showed a fair diffusion of the use of the minimally invasive approach in pancreatic surgery but with extremely variable ways and uses in the different territorial realities with evident and potentially risky paradoxes. Monitoring the diffusion of minimally invasive pancreatic surgery, the methods of application and the results of this approach has become of primary importance and for this reason the foundation of a national registry has been proposed by several scientific surgical societies.
This study aims to investigate what is the real diffusion of minimally invasive techniques in Italy and what postoperative outcomes the adoption of this approach generates.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Minimally invasive pancreatic surgery
Time frame: 90 days
any complication graded according to Clavien-Dindo classification
Time frame: 2 years
Disease recurrence or disease related death
Time frame: Intraoperative
Intraoperative conversion to open surgery for any reason
Time frame: Intraoperative
Variation of surgical time according to the registered case-load as operating surgeon and first assistant
Time frame: Intraoperative
Variation of intraoperative blood-loss according to the registered case-load as operating surgeon and first assistant
Time frame: Intraoperative
Variation of intraoperative complications rate according to the registered case-load as operating surgeon and first assistant
Time frame: Intraoperative
Variation of conversion rate according to the registered case-load as operating surgeon and first assistant
Contact information is provided by the study sponsor or research team.
Associazione Italiana per lo Studio del Pancreas
Other
Italian Registry of Minimally Invasive Pancreatic Surgery (IGOMIPS)
Acronym: IGOMIPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05603702
Chemically-Induced Disorders, Chronic Abdominal Pain
Stanford, California, United States
View Trial DetailsNCT07598357
Pancreatic Surgery
New York, United States
View Trial DetailsNCT07531420
Antibiotic Prophylaxis, Infections
Nancy, France
View Trial DetailsNCT07293104
Children, Pancreatic Surgery
View Trial Details